Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous plus oral vortioxetine versus oral vortioxetine in major depressive disorder
2015-005081-30Phase 2Completed
- Sponsor
- Lundbeck
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vortioxetine in major depressive disorder (MDD) (2 arms), sponsored by Lundbeck. Primary endpoint: Change from baseline to Week 1 in MADRS total score. Started Jun 2016; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2015-005081-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005081-30.